The complement pathway plays key roles in host defence, but its excessive activation or dysregulation can lead to a variety of disorders. This poster overviews strategies to therapeutically intervene ...

AJMC ®: How has treatment of complement-driven diseases changed since 2007, when the first complement inhibitor, eculizumab, was approved? SMITH: The development of eculizumab followed our ...